| Literature DB >> 30682878 |
Ayokanmi Ore1,2, Oluseyi Adeboye Akinloye3.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is a term that covers a range of hepatic disorders involving fat deposits in the liver. NAFLD begins with simple steatosis and progresses into non-alcoholic steatohepatitis (NASH) characterised by inflammation, fibrosis, apoptosis, oxidative stress, lipid peroxidation, mitochondrial dysfunction and release of adipokines and pro-inflammatory cytokines. Oxidative stress and antioxidants are known to play a vital role in the pathogenesis and severity of NAFLD/NASH. A number of oxidative stress and antioxidant markers are employed in the assessment of the pathological state and progression of the disease. In this article, we review several biomarkers of oxidative stress and antioxidants that have been measured at clinical and experimental levels. Also included is a comprehensive description of oxidative stress, sources and contribution to the pathogenesis of NAFLD/NASH.Entities:
Keywords: NAFLD; NASH; antioxidants; biomarkers; lipid peroxidation; liver; oxidative stress; reactive species
Mesh:
Substances:
Year: 2019 PMID: 30682878 PMCID: PMC6410206 DOI: 10.3390/medicina55020026
Source DB: PubMed Journal: Medicina (Kaunas) ISSN: 1010-660X Impact factor: 2.430
Figure 1Pathophysiology of NASH and the multi-hit hypothesis.
Major ROS and RNS of physiological importance.
|
|
| |
| Free Radicals | Hydroxyl radical ( | Decomposition of ONOO− or, HOCl |
| Superoxide radical ( | Electron transport systems, and one-electron reduction of O2 by respiratory burst via the action of membrane bound NADPH oxidase | |
| Peroxyl radical (ROO•) | Produced in the Fenton reaction | |
| Non-Radicals | Hydrogen peroxide (H2O2) | Activated macrophages during inflammation |
| Hypochlorous acid (HClO) | Combined activities of NADPH oxidase and myeloperoxidase (MPO) in phagocytes | |
| Lipid peroxides (ROOH) | Formed from oxidation of polyunsaturated fatty acid via lipid-peroxyl radical reaction | |
|
|
| |
| Free Radicals | Nitric oxide (NO•) | Nitric Oxide Synthase (NOS) |
| Nitrogen dioxide ( | Activated neutrophils | |
| Non-radicals | Dinitrogen trioxide (N2O3) | Produced in pathological conditions where (inducible nitric oxide (iNOS) is upregulated |
| Peroxinitrite (ONOO−) | Produced in pathological conditions where iNOS is upregulated | |
| Nitrite ( | Oxidation product from NO, formed during NOS activation in inflammatory diseases | |
| Nitryl ion ( | Activated neutrophils | |
Some important oxidative damage products.
| Macromolecule | Oxidative Damage | Damage Products |
|---|---|---|
| Lipids | Lipid oxidation/peroxidation | Malondialdehyde (MDA) |
| Proteins | Protein Oxidation, protein cross linkage, Oxidative modification of amino acids | Protein carbonyl compounds, |
| DNA | RNA/DNA fragmentation (single and double-strand breaks) | 8-hydroxy-2′-deoxyguanosine (8-OH-dG), 8-hydroxyguanine (8-OH-G) |
Physiologically important antioxidants and their functions.
| Antioxidant Type | Antioxidant Name | Functions |
|---|---|---|
| Enzymic antioxidants | Superoxide dismutase (SOD) | Converts |
| Catalase (CAT) | Converts H2O2 to 2H2O and O2 | |
| Glutathione peroxidase (GPx) | Detoxifies H2O2 and Lipid peroxides using reduced glutathione (GSH) producing the oxidised form of glutathione (GSSG) | |
| Glutathione reductase (GR) | Reduces GSSG to GSH | |
| Non-enzymic antioxidants | Ascorbic Acid (AA) | Detoxifies Superoxide radical, Hydroxyl radical, and H2O2 |
| Reduced Glutathione (GSH) | Neutralizes Superoxide radical, Hydroxyl radical, and H2O2; co-substrate for glutathione peroxidase | |
| α-Tocopherol | Detoxifies H2O2; protects against membrane lipid peroxidation (LPO) | |
| Ubiquinone | Detoxifies Lipid peroxides | |
| Thioredoxin (TRX) | General thiol redox control of protein activity via reversible disulfide formation | |
| Bilirubin | Effective in quenching/scavenging |
Sources of oxidative stress in NAFLD/NASH.
| Source | Contribution to OS in NAFLD/NASH | References |
|---|---|---|
| Mitochondrial metabolism (β-oxidation) | Production of ROS as a result of electron leakage during mitochondrial β-oxidation | [ |
| Peroxisomal β-oxidation | Generation of H2O2 during peroxisomal β-oxidation which is converted into hydroxyl radical contributing to OS | [ |
| Mitochondrial electron transport chain | inhibition of electron transport chain by TNF-α and lipid peroxidation products | [ |
| Microsomal Cytochrome P450 enzymes | ROS generation due to Increase in activity of cytochrome P4502E1 (CYP2E1) involved in lipooxygenation of longchain fatty acids | [ |
| Endoplasmic reticulum (ER) stress | Endoplasmic reticulum stress response, promotes OS via increased expression of CHOP (also called DDIT –DNA Damage Inducible Transcript-3 protein) | [ |
| Xanthine Oxidase (XO) | Increase in XO activity generates superoxide anions, due to induction by 4-HNE (a product of lipid peroxidation) | [ |
| Inflammatory Response | Abnormal inflammatory response mediated by gut microflora resulting in increase in pro-oxidants | [ |
Antioxidant markers measured in clinical NAFLD/NASH.
| Antioxidant Marker | Sample | Level/Activity/Expression in Sample | Clinical Case | Reference(s) |
|---|---|---|---|---|
|
| Serum | Decreased, Increased (nsc) | NASH | [ |
| Serum/Liver | Decreased | NAFLD | [ | |
| Plasma | Decreased | NAFLD | [ | |
| Blood | Increased | NAFLD | [ | |
| Liver | Decreased | NAFLD | [ | |
| Blood | Increased | NAFLD | [ | |
|
| Serum | Decreased, Increased (nsc) | NASH | [ |
| Plasma | Decreased | NAFLD | [ | |
| Blood | Increased | NAFLD | [ | |
| Liver | Decreased | NAFLD | [ | |
| Blood | Decreased | NAFLD | [ | |
|
| Serum | Decreased | NASH | [ |
| Blood | Increased | NAFLD | [ | |
| Liver | Decreased | NAFLD | [ | |
|
| Serum | Increased | NASH | [ |
| Blood | Increased | NAFLD | [ | |
|
| Serum | nsc | NASH | [ |
| Serum | Decreased | NAFLD | [ | |
|
| Serum | Increased | NASH | [ |
| Blood | Increased | NAFLD | [ | |
| Liver | Decreased | NAFLD | [ | |
| Blood | Decreased | NAFLD | [ | |
|
| Serum | Increased | NASH | [ |
| Serum | Decreased | NAFLD | [ | |
|
| Serum | Decreased | NAFLD | [ |
|
| Serum | Increased | NAFLD | [ |
|
| Serum | Decreased | NASH | [ |
| Serum | Decreased | NAFLD | [ |
nsc: no significant change.
Oxidative stress markers measured in clinical NAFLD/NASH.
| OS Marker | Sample | Level/Activity/Expression in Sample | Clinical Case | Reference(s) |
|---|---|---|---|---|
| Lipid peroxides | Plasma | Increased | NASH | [ |
| NO• | Serum | Increased | NASH | [ |
| Serum | Increased | NAFLD | [ | |
| Blood | Increased | NAFLD | [ | |
| TBARS/MDA | Serum | Increased | NAFLD | [ |
| Serum | Increased | NAFLD/NASH | [ | |
| Serum | Increased | NAFLD | [ | |
| Blood | Increased | NAFLD | [ | |
| Hydroperoxides | liver | Increased | NASH | [ |
| 8-Isoprostane | Plasma | Increased | NASH | [ |
| 4-HNE | Liver | Increased | NASH | [ |
| Protein carbonyl | Liver | Increased | NAFLD | [ |
| Nitrotyrosine | Blood | nsc | NAFLD | [ |
| 8-OH-dG | Liver | Increased | NASH | [ |
| Liver | Increased | NAFLD | [ | |
| CYP2E1 | Liver | Increased | NASH | [ |
| Liver | nsc | Steatosis/NASH | [ | |
| Liver | Increased | NAFLD | [ |
nsc: no significant change.
Antioxidant markers measured in experimental NAFLD/NASH.
| Antioxidant Marker | Sample | Level/Activity/Expression in Sample | Experimental Model | Experimental Specie | Reference(s) |
|---|---|---|---|---|---|
| SOD | Liver | Decreased | NASH (MCD) | Wistar Rats | [ |
| Liver | Increased | NASH (MCD) | C57BL/6 Mice | [ | |
| Liver | Increased | NASH (MCD) | C57BL/6 mice | [ | |
| Liver | Decreased | NASH (MCD) | C57BL6/J mice | [ | |
| Liver | Decreased | NASH (MCD) | N-Mary rats | [ | |
| Liver | Decreased | NAFLD (HFD) | Mice | [ | |
| Liver | Decreased | NASH (HF) | Kunming mice | [ | |
| Liver | Increased | NAFLD (HFD) | Rat | [ | |
| CAT | Liver | Decreased | NASH (MCD) | Wistar Rats | [ |
| Liver | Decreased | NASH (MCD) | C57BL/6 Mice | [ | |
| Liver | Increased | NASH (MCD) | C57BL/6 mice | [ | |
| Liver | Decreased | NASH (HCD) | Wistar Rats | [ | |
| Liver | Decreased | NAFLD (HFD) | Sprague-Dawley rats | [ | |
| GPx | Liver | Decreased | NASH (MCD) | Wistar Rats | [ |
| Liver | Increase | NASH (MCD) | N-Mary rats | [ | |
| Liver | Decreased | NAFLD (HFD) | Mice | [ | |
| Liver | Decreased | NASH (HF) | Kunming mice | [ | |
| Liver | nsc | NAFLD (HFD) | Sprague-Dawley rats | [ | |
| GR | Liver | Decreased | NASH (MCD) | N-Mary rats | [ |
| GSH | Liver | Decreased | NASH (MCD) | Wistar Rat | [ |
| Liver | Decreased | NASH (MCD) | N-Mary rats | [ | |
| Liver | Decreased | NAFLD (HFD) | Wistar Rats | [ | |
| Liver | Decreased | NAFLD (HCD) | Wistar Rats | [ | |
| Liver/RBC | Increased | NASH (HF-MCD) | Sprague-Dawley rats | [ | |
| Liver | Decreased | NASH (MCD) | Mice | [ |
MCD: Methionine/Choline Deficient Diet; HF: High fructose Diet; HFD: High Fat Diet; HCD: High Cholesterol diet; HF-MCD: High fat- methionine choline deficient diet; nsc: no significant change.
Oxidative stress markers measured in experimental NAFLD/NASH.
| OS Marker | Sample | Level/Activity/Expression in Sample | Experimental Model | Experimental Specie | Reference(s) |
|---|---|---|---|---|---|
| H2O2 | Liver | Increased | NASH (MCD) | C57BL/6J-mtFVB/N mice | [ |
| Nitrite/nitrate | Liver | Nsc | NAFLD (HFD) | Wistar Rats | [ |
| TBARS (MDA) | Liver | Increased | NASH | Rat | [ |
| Liver | Increased | NASH (MCD) | C57BL/6 Mice | [ | |
| Liver | Increased | Steatosis/NASH (HFD) | Albino rats | [ | |
| Liver | Increased | NASH (MCD) | C57BL/6 mice | [ | |
| Liver | Decreased | NAFLD (HCD) | Wistar Rats | [ | |
| Liver | Increased | Steatosis (HFD/HSD) | Wistar rats | [ | |
| Liver | Increased | HF/HGD | Wistar rats | [ | |
| Liver | Increased | NAFLD (HFD) | C57BL/6J mice | [ | |
| Liver | Increased | NASH (MCD) | C57BL/6 mice | [ | |
| Liver | Increased | NAFLD/NASH (CDAA diet) | Wistar Rats | [ | |
| Liver | Increased | NAFLD (HFD) | Sprague-Dawley rats | [ | |
| Liver | Increased | NASH (MCD) | C57BL6/J mice | [ | |
| Liver | Increased | NASH | Rat | [ | |
| Liver | Increased | NAFLD (HFD) | Wistar Rats | [ | |
| Liver | Increased | NASH (CDHF diet) | Wistar Rats | [ | |
| Liver | Increased | NASH (MCD) | N-Mary rats | [ | |
| Liver | Increased | NAFLD (HFD) | Mice | [ | |
| Liver | Increased | NASH (HF) | Kunming mice | [ | |
| Liver | Nsc | NASH (MCD) | C57BL/6J-mtFVB/N mice | [ | |
| Lipid peroxide | Liver | Increased | NASH (MCD) | Wistar Rat | [ |
| 8-Isoprostanes | Liver | Increased | NASH (HFMCD) | Sprague Dawley Rat | [ |
| 4-HNE | Liver | Increased | NASH (MCD) | Wistar Rat | [ |
| Liver | Increased | NASH | Rat | [ | |
| Liver | Increased | NASH (HFD) | Sprague Dawley Rat | [ | |
| Liver | Increased | NASH (CDHF diet) | Wistar Rats | [ | |
| Liver | Increased | NASH | leptin-deficient (ob/ob) mice | [ | |
| Liver | Increased | NASH (HF-HSD) | C57BL/6 J mice | [ | |
| Liver | Increased | NASH (MCD) | C57BL6 mice | [ | |
| Protein carbonyl | Liver | Increased | NASH (MCD) | N-Mary rats | [ |
| Nitrotyrosine | Liver | Increased | NAFLD | CYP2E1 transgenic (Tg) mice | [ |
| Dityrosine | Liver | Increased | NAFLD (HFD) | C57BL/6J mice | [ |
| Hydroxyproline | Liver | Increased | NAFLD/NASH (CDAA diet) | Wistar Rats | [ |
| Liver | Increased | NASH (MCD/WD) | C57BL6 mice | [ | |
| 8-OH-dG | Liver | Increased | NASH (MCD) | Wistar Rat | [ |
| Liver | Decreased | NASH (HF-MCD) | Sprague-Dawley rats | [ | |
| Liver | Increased | NAFLD (HFD) | C57BL/6J mice | [ | |
| CYP2E1 | Liver | Increased | NAFLD | CYP2E1 transgenic (Tg) mice | [ |
| Liver | Increased | NASH (HFD) | Sprague Dawley Rat | [ | |
| Liver | Increased | NASH (HFD) | Sprague Dawley Rat | [ | |
| Liver | Increased | Steatosis (HFD/HSD) | Wistar rats | [ | |
| Liver | Increased | NASH (HFD) | Sprague-Dawley rats | [ | |
| Liver | Increased | NASH (CDHF diet) | Wistar rats | [ | |
| NADPH Oxidase | liver | Increased | NASH | ob/ob mice | [ |
| Xanthine Oxidase | Liver | Increased | NAFLD (HFD) | Sprague-Dawley rats | [ |
MCD: Methionine/Choline Deficient Diet; HF: High fructose Diet; HFD: High Fat Diet; HCD: High Cholesterol diet; HSD: High Sucrose diet; CDAA: Choline Deficient L-Amino Acid-defined; CDHF: Choline Deficient High Fat diet; HFMCD: High fat methionine choline deficient diet; HF-HSD: High fat-high sucrose diet; WD: Western diet; HF/HGD: High-Fructose/High-Glucose Diet; nsc: no significant change.